消癥抑癌方对卵巢癌SKOV3细胞增殖、迁移的影响

doi:10.6040/j.issn.1671-7554.0.2023.0001

摘要/Abstract

摘要： 目的探讨消癥抑癌方对人卵巢癌细胞SKOV3增殖和迁移的影响及潜在作用机制。方法利用网络药理学分析消癥抑癌方抗卵巢癌的关键活性成分和核心靶点,并通过基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析筛选其相关生物学过程和通路。制备消癥抑癌方含药血清,用含药血清处理卵巢癌SKOV3细胞。采用CCK-8法和EdU染色法检测消癥抑癌方含药血清对SKOV3细胞增殖的影响;采用划痕实验和Transwell迁移实验检测消癥抑癌方含药血清对SKOV3细胞迁移的影响;采用Western blotting法检测消癥抑癌方含药血清对SKOV3细胞自噬蛋白(P62)、自噬相关蛋白3(ATG3)、微管相关蛋白1轻链3 B(LC3B)及腺苷酸活化蛋白激酶(AMPK)/蛋白激酶B(AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)通路相关蛋白的影响。结果网络药理学研究显示,消癥抑癌方抗卵巢癌的关键活性成分是槲皮素、山柰酚、木犀草素、汉黄芩素、柚皮素等,核心靶点是MAPK3、AKT1、SRC、MAPK1、TP53等。KEGG富集分析共得到171条通路(P<0.01),其中Degree值排名较靠前且与卵巢癌相关的通路主要涉及癌症通路、PI3K-AKT通路、MAPK通路、AMPK通路、自噬、mTOR通路等。体外实验结果表明,与对照组相比,10%和20%含药血清组SKOV3细胞存活率和EdU阳性细胞率均降低(P<0.001),细胞迁移率下降(P<0.001),迁移细胞数也减少(P<0.01或P<0.001)。Western blotting结果表明,10%和20%含药血清干预后,P62、ATG3、LC3B-Ⅱ蛋白表达水平均上调(P<0.05或P<0.01或P<0.001),p-AMPK/AMPK的表达水平上调(P<0.001),p-AKT/AKT和p-mTOR/mTOR的表达水平降低(P<0.05或P<0.01)。结论消癥抑癌方抑制卵巢癌SKOV3细胞的增殖和迁移,其作用机制可能与调控AMPK/AKT/mTOR通路,进而阻断自噬流有关。

关键词: 消癥抑癌方, 卵巢癌, 增殖, 迁移, 自噬, 腺苷酸活化蛋白激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白

Abstract: Objective To investigate the effects of Xiaozheng Yiai decoction on the proliferation and migration of ovarian cancer SKOV3 cells and to explore the underlying mechanism. Methods The key active components and core targets of the decoction against ovarian cancer were analyzed with network pharmacology, and the related biological processes and pathways were screened with gene ontology(GO)and Kyoto Encyclopedia of genes and genomes(KEGG)enrichment analysis. Serum containing Xiaozheng Yiai decoction was prepared and SKOV3 cells were treated with it. Its effects on the proliferation of SKOV3 cells was detected with CCK-8 and EdU staining; its effects on the migration of SKOV3 cells was determined with wound healing assay and Transwell migration assay; its effects on the autophagy protein(P62), autophagy-related protein 3(ATG3), microtubule-associated protein 1 light chain 3 Beta(LC3B)and adenosine 5-monophosphate-activated protein kinase(AMPK)/ protein kinase B(AKT)/ mammalian target of rapamycin(mTOR)pathway related proteins in SKOV3 cells were assessed with Western blotting. Results Network pharmacology studies showed that the key active components of Xiaozheng Yiai decoction against ovarian cancer were quercetin, kaempferol, luteolin, wogonin, naringenin, and the core targets were MAPK3, AKT1, SRC, MAPK1, TP53, and so on. KEGG enrichment analysis identified 171 pathways(P<0.01). The pathways with the highest Degree ranking and associated with ovarian cancer mainly involved the cancer pathway, PI3K-AKT pathway, MAPK pathway, AMPK pathway, autophagy, and mTOR pathway. The results of in vitro experiments showed that compared with the control group, the 10% and 20% drug-containing serum groups had decreased cell viability, EdU positive cell rate, cell migration, and number of migrating cells(all P<0.001). The results of Western blotting showed that the protein expression levels of P62, ATG3 and LC3B-II were up-regulated after treatment with 10% and 20% drug-containing serum(all P<0.05), the p-AMPK/AMPK ratio was up-regulated(P<0.001), and the expression levels of p-AKT/AKT and p-mTOR/mTOR decreased (P<0.05 or P<0.01). Conclusion Xiaozheng Yiai decoction can inhibit the proliferation and migration of ovarian cancer SKOV3 cells, possibly via the regulation of AMPK/AKT/mTOR pathway and the blocking of autophagic flux.

Key words: Xiaozheng Yiai decoction, Ovarian cancer, Proliferation, Migration, Autophagy, Adenosine 5-monophosphate-activated protein kinase / protein kinase B / mammalian target of rapamycin

中图分类号:

R737.31

何静,严如根,武志红,李长忠. 消癥抑癌方对卵巢癌SKOV3细胞增殖、迁移的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 1-10.

HE Jing, YAN Rugen, WU Zhihong, LI Changzhong. Effects of Xiaozheng Yiai decoction on the proliferation and migration of ovarian cancer SKOV3 cells[J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 1-10.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer [J]. Methods Mol Biol, 2009, 472: 413-437. doi: 10.1007/978-1-60327-492-0_20.
[3] Haldar K, Gaitskell K, Bryant A, et al. Epidermal growth factor receptor blockers for the treatment of ovarian cancer [J]. Cochrane Database Syst Rev, 2009(4): CD007927. doi: 10.1002/14651858.cd007927.pub2.
[4] Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science [J]. Cancer Med, 2019, 8(5): 1958-1975.
[5] 张静, 高冬冬. 扶正生髓汤对卵巢癌术后化疗减毒增效作用及机制研究[J]. 中华中医药学刊, 2019, 37(9): 2242-2245. ZHANG Jing, GAO Dongdong. Toxicity reducing and efficacy enhancing and mechanism research of Fuzheng Shengsui decoction in treatement of ovarian cancer postoperative patients after chemotherapy [J]. Chinese Journal of Traditional Chinese Medicine, 2019, 37(9): 2242-2245.
[6] 谢辉, 陈四明, 刘仁榷, 等. 健脾解毒消癌方治疗晚期卵巢癌30例临床观察[J]. 湖南中医杂志, 2022, 38(6): 12-15. XIE Hui, CHEN Siming, LIU Renque, et al. Clinical effect of Jianpi Jiedu Xiaoai prescription in treatment of advanced ovarian cancer: an analysis of 30 cases [J]. Hunan Journal of Traditional Chinese Medicine, 2022, 38(6): 12-15.
[7] Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform, 2014, 6: 13. doi:10.1186/1758-2946-6-13.
[8] Kim S, Chen J, Cheng TJ, et al. PubChem in 2021: new data content and improved web interfaces [J]. Nucleic Acids Res, 2021, 49(1): 1388-1395.
[9] Daina A, Michielin O, Zoete V. SwissTarge-tPrediction: updated data and new features for efficient prediction of protein targets of small molecules [J]. Nucleic Acids-Res, 2019, 47(1): 357-364.
[10] Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses [J]. Curr Protoc Bioinformatics, 2016, 54: 1.30.1-1.30.33. doi: 10.1002/cpbi.5.
[11] Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org: Online Mendelian Inheritance in Man(OMIM^®), an online catalog of human genes and genetic disorders [J]. Nucleic Acids Res, 2015, 43(1): 789-798.
[12] Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customiza-ble protein-protein networks, and functional characterization of user-uploaded gene/measurement sets [J]. Nucleic Acids Res, 2021, 49(1): 605-612.
[13] Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources [J]. Nat Protoc, 2009, 4(1): 44-57.
[14] Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists [J]. Nucleic Acids Res, 2009, 37(1): 1-13.
[15] Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human [J]. J Basic Clin Pharm, 2016, 7(2): 27-31.
[16] Li K, You F, Zhang Q, et al. Chemical and biological evidence of the efficacy of Shengxian Decoction for treating human lung adenocarcinoma [J]. Front Oncol, 2022, 12: 849579. doi: 10.3389/fonc.2022.849579.
[17] 杨霖, 王笑民, 杨国旺, 等. “虚、痰、瘀、毒”在卵巢癌发生发展及转移过程中的理论探讨[J]. 时珍国医国药, 2018, 29(8): 1951-1952. YANG Lin, WANG Xiaomin, YANG Guowang, et al. Theoretical discussion of "deficiency, phlegm, stasis and poison" in the process of occurrence, development and metastasis of ovarian cancer [J]. Lishizhen Medicine and Materia Medica Research, 2018, 29(8): 1951-1952.
[18] 乔红丽, 侯炜, 李站, 等. 朴炳奎治疗卵巢癌辨证思路及用药规律总结[J]. 北京中医药, 2014, 33(10): 735-738. QIAO Hongli, HOU Wei, LI Zhan, et al. Summary of syndrome differentiation and medication rules of Piao Bingkui in the treatment of ovarian cancer [J]. Beijing Journal of Traditional Chinese Medicine, 2014, 33(10): 735-738.
[19] 陈聪. 中药单体槲皮素通过抑制LSD1干预上皮性卵巢癌侵袭的机制研究[D]. 南京: 南京中医药大学, 2017.
[20] Gao Y, Yin J, Rankin GO, et al. Kaempferol induces G2/M cell cycle arrest via checkpoint kinase 2 and promotes apoptosis vi-a death receptors in human ovarian carcinoma A2780/CP70 cells [J]. Molecules, 2018, 23(5): E1095.
[21] 易均路, 侯科名, 陈蓉. 木犀草素对人卵巢癌SKOV3细胞增殖与凋亡的影响[J]. 中药新药与临床药理, 2020, 31(2): 125-133. YI Junlu, HOU Keming, CHEN Rong. Effects of luteolin on proliferation and apoptosis of human ovarian cancer cell line SKOV3 [J]. Traditional Chinese Drug Research and Clinical Pharmacology, 2020, 31(2): 125-133.
[22] Ruibin J, Bo J, Danying W, et al. Therapy effects of wogonin on ovarian cancer cells [J]. Biomed Res Int, 2017, 2017: 9381513. doi: 10.1155/2017/9381513.
[23] Lin C, Zeng Z, Lin Y, et al. Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota [J]. Phytomedicine, 2022, 106: 154401. doi: 10.1016/j.phymed.2022.154401.
[24] Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer [J]. Mol Cancer, 2020, 19(1): 12.
[25] Maulucci G, Chiarpotto M, Papi M, et al. Quantitative analysis of autophagic flux by confocal pH-imaging of autophagic intermediates [J]. Autophagy, 2015, 11(10): 1905-1916.
[26] Kabeya Y, Mizushima N, Ueno T, et al. L-C3, a mammalian homologue of yeast Apg-8p, is localized in autophagosome membranes after processing [J]. EMBO J, 2000, 19(21): 5720-5728.
[27] Yoshii SR, Mizushima N. Monitoring and measuring autophagy [J]. Int J Mol Sci, 2017, 18(9): E1865.
[28] Mihaylova MM, Shaw RJ. The AMPK sign-alling pathway coordinates cell growth, autophagy and metabolism [J]. Nat Cell Biol, 2011, 13(9): 1016-1023.
[29] Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy [J]. FEBS Lett, 2010, 584(7): 1287-1295.
[30] Yu L, McPhee CK, Zheng L, et al. Termination of autophagy and reformation of lysosomes regulated by mTOR [J]. Nature, 2010, 465(7300): 942-946.
[31] Gao LK, Wang Z, Lu DH, et al. Paeonol i-nduces cytoprotective autophagy via blockiqng the Akt/mTOR pathway in ovarian cancer cells [J]. Cell Death Dis, 2019, 10(8): 609.
[32] Fan X, Xie M, Zhao F, et al. Daphnetin tr-iggers ROS-induced cell death and induces cytoprotective autophagy by modulating th-e AMPK/Akt/mTOR pathway in ovarian cancer [J]. Phytomedicine, 2021, 82: 153465. doi: 10.1016/j.phymed.2021.153465.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed